Report cover image

Amicus Therapeutics Inc - Strategic SWOT Analysis Review

Publisher GlobalData
Published May 04, 2026
Length 42 Pages
SKU # GBDT21162311

Description

Amicus Therapeutics Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – GlobalData’s summarization of the company’s business strategy.
  • SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
Highlights

Amicus Therapeutics Inc (Amicus Therapeutics) is a biotechnology company. It focuses on the research, development, and commercialization of small molecule drugs. These drugs, known as pharmacological chaperones, are orally administered for the treatment of rare and orphan diseases. The company offers Galafold (migalastat), a small molecule that is indicated for the treatment of Fabry disease; and Pombiliti and Opfolda, for the treatment of Pompe disease in adults. DMX-200 is a small molecule inhibitor of the chemokine receptor 2 (CCR2) under development in a pivotal Phase 3 study (ACTION3), for the treatment of FSGS kidney disease. The company has a presence in the US, the UK, Switzerland, Italy, Ireland, Germany, Spain, and Japan. Amicus Therapeutics is headquartered in Princeton, New Jersey, the US.

Reasons to Buy
  • Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
  • Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
  • Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
  • Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note:Some sections may be missing if data is unavailable for the company.

Table of Contents

42 Pages
Section 1 - About the Company
Amicus Therapeutics Inc - Key Facts
Amicus Therapeutics Inc - Key Employees
Amicus Therapeutics Inc - Key Employee Biographies
Amicus Therapeutics Inc - Major Products and Services
Amicus Therapeutics Inc - History
Amicus Therapeutics Inc - Company Statement
Amicus Therapeutics Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Amicus Therapeutics Inc - Business Description
Product Category: Galafold
Performance
Product Category: Pombiliti + Opfolda
Performance
Geographical Segment: Ex-U.S
Performance
Geographical Segment: U.S
Performance
R&D Overview
Amicus Therapeutics Inc - Corporate Strategy
Amicus Therapeutics Inc - SWOT Analysis
SWOT Analysis - Overview
Amicus Therapeutics Inc - Strengths
Amicus Therapeutics Inc - Weaknesses
Amicus Therapeutics Inc - Opportunities
Amicus Therapeutics Inc - Threats
Amicus Therapeutics Inc - Key Competitors
Section 3 – Company’s Lifesciences Financial Deals and Alliances
Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
Amicus Therapeutics Inc, Recent Deals Summary
Section 4 – Company’s Recent Developments
May 01, 2025: Amicus Therapeutics Announces First Quarter 2025 Financial Results and Corporate Updates
Feb 19, 2025: Amicus Therapeutics Announces Full-Year 2024 Financial Results and Corporate Updates
Feb 10, 2025: Amicus Therapeutics to Announce Full-Year 2024 Financial Results on February 19, 2025
Feb 03, 2025: Amicus Therapeutics Announces Presentations and Posters at the 21st Annual WORLDSymposium 2025
Jan 12, 2025: Amicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic Outlook
Section 5 – Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List of Tables
Amicus Therapeutics Inc, Key Facts
Amicus Therapeutics Inc, Key Employees
Amicus Therapeutics Inc, Key Employee Biographies
Amicus Therapeutics Inc, Major Products and Services
Amicus Therapeutics Inc, History
Amicus Therapeutics Inc, Other Locations
Amicus Therapeutics Inc, Subsidiaries
Amicus Therapeutics Inc, Key Competitors
Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
Amicus Therapeutics Inc, Recent Deals Summary
List of Figures
Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2020 to YTD 2026

Search Inside Report

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us